This investigation revealed that high expression of the SUR2 gene is associated with improved overall survival (OS) in all ovarian cancer patients [Hazard Ratio (HR)= 0.7 (0.55-0.86); Figures 1E–G] with a 49% reduction in mortality and improved progression-free survival PFS [HR=0.73 (0.6–0.88); Figure 1H]. This evidence concerns the gene ABCC9 and ovarian carcinoma.